TY - JOUR AU - Germain, D. P. PY - 2010 DA - 2010// TI - Fabry disease JO - Orphanet J Rare Dis VL - 5 UR - https://doi.org/10.1186/1750-1172-5-30 DO - 10.1186/1750-1172-5-30 ID - Germain2010 ER - TY - JOUR AU - Eng, C. M. AU - Guffon, N. AU - Wilcox, W. R. PY - 2001 DA - 2001// TI - Safety and efficacy of recombinant human a-galactosidase A – replacement therapy in Fabry's disease JO - N Engl J Med VL - 345 UR - https://doi.org/10.1056/NEJM200107053450102 DO - 10.1056/NEJM200107053450102 ID - Eng2001 ER - TY - JOUR AU - Schiffmann, R. AU - Kopp, J. B. AU - Austin, H. A. PY - 2001 DA - 2001// TI - Enzyme replacement therapy in Fabry disease: a randomized controlled trial JO - JAMA VL - 285 UR - https://doi.org/10.1001/jama.285.21.2743 DO - 10.1001/jama.285.21.2743 ID - Schiffmann2001 ER - TY - JOUR AU - Alfhadel, M. AU - Sirrs, S. PY - 2011 DA - 2011// TI - Enzyme replacement therapy for Fabry disease: some answers but more questions JO - Ther Clin Risk Management VL - 7 ID - Alfhadel2011 ER - TY - JOUR AU - Fan, J. Q. AU - Ishii, S. AU - Asano, N. AU - Suzuki, Y. PY - 1999 DA - 1999// TI - Accelerated transport and maturation of lysosomal a-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor JO - Nature Med VL - 5 UR - https://doi.org/10.1038/4801 DO - 10.1038/4801 ID - Fan1999 ER - TY - JOUR AU - Ishii, S. AU - Chang, H. H. AU - Kawasaki, K. PY - 2007 DA - 2007// TI - Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin JO - Biochem J VL - 406 UR - https://doi.org/10.1042/BJ20070479 DO - 10.1042/BJ20070479 ID - Ishii2007 ER - TY - JOUR AU - Yam, G. H. AU - Zuber, C. AU - Roth, J. PY - 2005 DA - 2005// TI - A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder JO - FASEB J VL - 19 UR - https://doi.org/10.1096/fj.04-2375com DO - 10.1096/fj.04-2375com ID - Yam2005 ER - TY - JOUR AU - Benjamin, E. R. AU - Flanagan, J. J. AU - Schilling, A. PY - 2009 DA - 2009// TI - The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines JO - J Inherit Metab Dis VL - 32 UR - https://doi.org/10.1007/s10545-009-1077-0 DO - 10.1007/s10545-009-1077-0 ID - Benjamin2009 ER - TY - JOUR AU - Khanna, R. AU - Soska, R. AU - Lun, Y. PY - 2010 DA - 2010// TI - The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2009.220 DO - 10.1038/mt.2009.220 ID - Khanna2010 ER - TY - JOUR AU - Mayes, J. S. AU - Scheerer, J. B. AU - Sifers, R. N. AU - Donaldson, M. L. PY - 1981 DA - 1981// TI - Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease JO - Clin Chim Acta VL - 112 UR - https://doi.org/10.1016/0009-8981(81)90384-3 DO - 10.1016/0009-8981(81)90384-3 ID - Mayes1981 ER - TY - JOUR AU - Wu, X. AU - Katz, E. AU - Della Valle, C. PY - 2011 DA - 2011// TI - A pharmacogenetic approach to identify mutant forms of α-Galactosidase A that respond to a pharmacological chaperone for Fabry disease JO - Hum Mutat VL - 2 UR - https://doi.org/10.1002/humu.21530 DO - 10.1002/humu.21530 ID - Wu2011 ER - TY - JOUR AU - Roddy, T. P. AU - Nelson, B. C. AU - Sung, C. C. PY - 2005 DA - 2005// TI - Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy JO - Clin Chem VL - 51 UR - https://doi.org/10.1373/clinchem.2004.038323 DO - 10.1373/clinchem.2004.038323 ID - Roddy2005 ER - TY - JOUR AU - Fuller, M. AU - Sharp, P. C. AU - Rozaklis, T. PY - 2005 DA - 2005// TI - Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes JO - Clin Chem VL - 51 UR - https://doi.org/10.1373/clinchem.2004.041418 DO - 10.1373/clinchem.2004.041418 ID - Fuller2005 ER - TY - JOUR AU - Thurberg, B. L. AU - Rennke, H. AU - Colvin, R. B. PY - 2002 DA - 2002// TI - Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy JO - Kidney Int VL - 62 UR - https://doi.org/10.1046/j.1523-1755.2002.00675.x DO - 10.1046/j.1523-1755.2002.00675.x ID - Thurberg2002 ER - TY - JOUR AU - Barisoni, L. AU - Jennette, J. C. AU - Colvin, R. PY - 2012 DA - 2012// TI - Novel Quantitative Virtual Microscopy-Based method to evaluate GL-3 inclusions in renal peritubular capillaries in patients with Fabry disease JO - Arch Pathol Lab Med VL - 136 UR - https://doi.org/10.5858/arpa.2011-0350-OA DO - 10.5858/arpa.2011-0350-OA ID - Barisoni2012 ER - TY - JOUR AU - Fan, J. Q. AU - Ishii, S. PY - 2007 DA - 2007// TI - Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors JO - FEBS J VL - 274 UR - https://doi.org/10.1111/j.1742-4658.2007.06041.x DO - 10.1111/j.1742-4658.2007.06041.x ID - Fan2007 ER - TY - JOUR AU - Germain, D. P. AU - Fan, J. Q. PY - 2009 DA - 2009// TI - Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies JO - Int J Clin Pharmacol Ther VL - 47 UR - https://doi.org/10.5414/CPP47111 DO - 10.5414/CPP47111 ID - Germain2009 ER - TY - JOUR AU - Banikazemi, M. AU - Bultas, J. AU - Waldek, S. PY - 2007 DA - 2007// TI - Agalsidase-beta therapy for advanced Fabry disease: a randomized trial JO - Ann Intern Med VL - 146 UR - https://doi.org/10.7326/0003-4819-146-2-200701160-00148 DO - 10.7326/0003-4819-146-2-200701160-00148 ID - Banikazemi2007 ER - TY - JOUR AU - Kitagawa, T. AU - Ishige, N. AU - Suzuki, K. PY - 2005 DA - 2005// TI - Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry JO - Mol Genet Metab VL - 85 UR - https://doi.org/10.1016/j.ymgme.2005.01.007 DO - 10.1016/j.ymgme.2005.01.007 ID - Kitagawa2005 ER - TY - JOUR AU - Schiffmann, R. AU - Waldek, S. AU - Benigni, A. AU - Auray-Blais, C. PY - 2010 DA - 2010// TI - Biomarkers of Fabry Disease Nephropathy JO - Clin J Am Soc Nephrol VL - 5 UR - https://doi.org/10.2215/CJN.06090809 DO - 10.2215/CJN.06090809 ID - Schiffmann2010 ER - TY - JOUR AU - Auray-Blais, C. AU - Millington, D. S. AU - Barr, C. AU - Young, S. P. AU - Mills, K. AU - Clarke, J. T. PY - 2009 DA - 2009// TI - Gb(3)/creatinine biomarkers for Fabry disease: issues to consider JO - Mol Genet Metab VL - 97 UR - https://doi.org/10.1016/j.ymgme.2009.04.006 DO - 10.1016/j.ymgme.2009.04.006 ID - Auray-Blais2009 ER - TY - JOUR AU - Najafian, B. AU - Svarstad, E. AU - Bostad, L. PY - 2011 DA - 2011// TI - Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease JO - Kidney Int VL - 79 UR - https://doi.org/10.1038/ki.2010.484 DO - 10.1038/ki.2010.484 ID - Najafian2011 ER - TY - JOUR AU - Whybra, C. AU - Kampmann, C. AU - Willers, I. PY - 2001 DA - 2001// TI - Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes JO - J Inherit Metab Dis VL - 24 UR - https://doi.org/10.1023/A:1012993305223 DO - 10.1023/A:1012993305223 ID - Whybra2001 ER - TY - JOUR AU - Wilcox, W. R. AU - Oliveira, J. P. AU - Hopkin, R. J. PY - 2008 DA - 2008// TI - Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry JO - Mol Genet Metab VL - 93 UR - https://doi.org/10.1016/j.ymgme.2007.09.013 DO - 10.1016/j.ymgme.2007.09.013 ID - Wilcox2008 ER - TY - JOUR AU - Kuznetsov, G. AU - Nigam, S. K. PY - 1998 DA - 1998// TI - Folding of secretory and membrane proteins JO - N Engl J Med VL - 339 UR - https://doi.org/10.1056/NEJM199812033392307 DO - 10.1056/NEJM199812033392307 ID - Kuznetsov1998 ER - TY - JOUR AU - Bradbury, J. PY - 2003 DA - 2003// TI - Chaperones: Keeping a close eye on protein folding JO - Lancet VL - 361 UR - https://doi.org/10.1016/S0140-6736(03)12975-3 DO - 10.1016/S0140-6736(03)12975-3 ID - Bradbury2003 ER - TY - JOUR AU - Cohen, F. E. AU - Kelly, J. W. PY - 2003 DA - 2003// TI - Therapeutic approaches to protein-misfolding diseases JO - Nature VL - 426 UR - https://doi.org/10.1038/nature02265 DO - 10.1038/nature02265 ID - Cohen2003 ER -